MR tool can diagnose difficult cases of ovarian cancer

MR tool can diagnose difficult cases of ovarian cancer

Press releases may be edited for formatting or style | January 31, 2020 MRI
The tool has produced encouraging results in a clinical study and its impact on management and outcomes of women with ovarian cancer will now be evaluated in a major trial at 18 hospitals in the UK, including Imperial College Healthcare NHS Trust.

The tool is able to distinguish between malignant and benign ovarian cysts with 90 per cent accuracy, in cases that cannot be distinguished on ultrasound. It was developed by researchers led by Professor Isabelle Thomassin-Naggara at the APHP-Sorbonne Université, with Professor Andrea Rockall at Imperial College London.

Currently, to investigate potential cases of ovarian cancer doctors use ultrasound scanning and blood tests. However, in a quarter of cases these methods cannot identify with confidence whether a patient's cyst in benign or malignant. This leads to surgical investigations, which are invasive and carry risks, such as potential loss of fertility. In most cases women are then diagnosed as having benign cysts.

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

The team believes that the new tool can be used as a triage test to decide whether patients need further follow up or treatment. They also believe that the findings from the study, published in the JAMA Network Open, could help stratify patients who are high risk so they can be given treatment at a much earlier stage.

Professor Andrea Rockall, senior author of the study and Chair of Radiology at Imperial College London, said:

"Ovarian cancer is referred to as a 'silent killer' as cases are often diagnosed at an advanced stage of the disease. When it is diagnosed earlier the chance of survival is much improved.

There is a real unmet clinical need to find less invasive ways to identify women at risk of ovarian cancer. Our tool has the potential to help triage patients who are low risk so they can have less invasive treatment options, as well as identifying high risk patients so they can receive treatment at an earlier stage and have a better chance of long-term survival."

Ovarian cancer is the sixth most common cancer in women and usually affects women after the menopause or those with a family history of the disease. There are 6,000 new cases of ovarian cancer a year in the UK but the long-term survival rate is just 35-40 per cent as the disease is often diagnosed at a late stage once symptoms such as bloating are noticeable. Early detection of the disease could improve survival rates.

Currently, to investigate potential cases of ovarian cancer clinicians use an ultrasound of the pelvis which shows the ovaries, womb and surrounding structures. They look for cysts in the ovaries and if these look suspicious, women are referred for additional investigations. Clinicians also use a blood test to look for a substance called CA125 - an indication of cancer. These methods are effective at differentiating most benign cysts with those that are malignant. However, in 20-25 per cent of cases the ultrasound is unable to confidently characterise whether a cyst is malignant or benign.

You Must Be Logged In To Post A Comment